The role of microRNA-4723-5p regulated by c-myc in triple-negative breast cancer

References

• Beiki O, Hall P, Ekbom A, et al. Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: a population-based cohort study. Bcr. 2012;14:R5.
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.
   PubMed Web of Science ®Google Scholar
• Rhodes LV, Tate CR, Hoang VT, et al. Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. Oncogenesis. 2015;4:e168.
   PubMed Web of Science ®Google Scholar
• Shah AN, Metzger O, Bartlett CH, et al. Hormone receptor-positive/human epidermal growth receptor 2-negative metastatic breast cancer in young women: emerging data in the era of molecularly targeted agents. Oncologist. 2020;25:e900–e908.
   PubMed Web of Science ®Google Scholar
• Anders CK, Abramson V, Tan T, et al. The evolution of triple-negative breast cancer: from biology to novel therapeutics. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting, San Francisco, USA 2016; 35: 34–42
   Google Scholar
• Karagoz K, Sinha R, Arga KY. Triple negative breast cancer: a multi-omics network discovery strategy for candidate targets and driving pathways. OMICS. 2015;19:115–130.
   PubMed Web of Science ®Google Scholar
• Mathsyaraja H, Eisenman RN. Parsing Myc Paralogs in Oncogenesis. Cancer Cell. 2016;29:1–2.
   PubMed Web of Science ®Google Scholar
• Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395–399.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–990.
   PubMed Web of Science ®Google Scholar
• Gwak JM, Kim HJ, Kim EJ, et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res Treat. 2014;147:39–49.
   PubMed Web of Science ®Google Scholar
• Gravgaard KH, Lyng MB, Laenkholm AV, et al. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat. 2012;134:207–217.
   PubMed Web of Science ®Google Scholar
• Kolacinska A, Morawiec J, Pawlowska Z, et al. Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients. DNA Cell Biol. 2014;33:624–629.
   PubMed Web of Science ®Google Scholar
• Sai S, Ichikawa D, Tomita H, et al. Quantification of plasma cell-free DNA in patients with gastric cancer. Anticancer Res. 2007;27:2747–2751.
   PubMed Web of Science ®Google Scholar
• Vinayanuwattikun C, Winayanuwattikun P, Chantranuwat P, et al. The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer. J Cancer Res Clin Oncol. 2013;139:67–76.
   PubMed Web of Science ®Google Scholar
• Shin VY, Siu JM, Cheuk I, et al. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 2015;112:1751–1759.
   PubMed Web of Science ®Google Scholar
• Mathe A, Scott RJ, Avery-Kiejda KA. MiRNAs and other epigenetic changes as biomarkers in triple negative breast cancer. Int J Mol Sci. 2015;16:28347–28376.
   PubMed Web of Science ®Google Scholar
• Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721–1726.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang M, Wang C. Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. J Clin Lab Anal. 2020;34:e23233.
   PubMed Web of Science ®Google Scholar
• Yue S, Ye X, Zhou T, et al. PGRN(-/-) TAMs-derived exosomes inhibit breast cancer cell invasion and migration and its mechanism exploration. Life Sci. 2021;264:118687.
   PubMed Web of Science ®Google Scholar
• Wei Z, Lyu B, Hou D, et al. Mir-5100 mediates proliferation, migration and invasion of oral squamous cell carcinoma cells via targeting SCAI. J Invest Surg. 2021;34:834–841.
   PubMed Web of Science ®Google Scholar
• Avery-Kiejda KA, Mathe A, Scott RJ. Genome-wide miRNA, gene and methylation analysis of triple negative breast cancer to identify changes associated with lymph node metastases. Genom Data. 2017;14:1–4.
   PubMedGoogle Scholar
• Schultz DJ, Muluhngwi P, Alizadeh-Rad N, et al. Genome-wide miRNA response to anacardic acid in breast cancer cells. PloS One. 2017;12:e0184471.
   PubMed Web of Science ®Google Scholar
• Mitra S. MicroRNA therapeutics in triple negative breast cancer. Archives of Pathology and Clinical Research. 2017; Arch Pathol Clin Res. 1:009–017.
   Google Scholar
• Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17:10–12.
   Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
   PubMed Web of Science ®Google Scholar
• Wong N, Wang X, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146–152.
   PubMed Web of Science ®Google Scholar
• Conesa A, Gotz S, Garcia-Gomez JM, et al. Blast2GO: a universal tool for annotation, visualization and analysis in functional genomics research. Bioinformatics. 2005;21:3674–3676.
   PubMed Web of Science ®Google Scholar
• Pratama MY, Cavalletto L, Tiribelli C, et al. Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma. Sci Rep. 2020 Feb 21; 10(1):3128.
   PubMed Web of Science ®Google Scholar
• Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012;209:679–696.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Festuccia C, Popov VM, et al. c-Myc sustains transformed phenotype and promotes radioresistance of embryonal rhabdomyosarcoma cell lines. Radiat Res. 2016;185:411–422.
   PubMed Web of Science ®Google Scholar
• Zhang F, Luo BH, Wu QH, et al. LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b. Mol Med. 2022 Jan 4;28(1):2. PMID: 34983361; PMCID: PMC8725507.
   PubMed Web of Science ®Google Scholar
• Qiu H, Song H, Luo M, et al. Dysfunction of apoptosis and autophagy correlates with local recurrence in esophageal squamous cell carcinoma after definitive chemoradiation. Cancer Cell Int. 2021 Sep 6;21(1):466. PMID: 34488754; PMCID: PMC8419897.
   PubMed Web of Science ®Google Scholar
• Yu W, Singh R, Wang Z, et al. The E3 ligase TRAF4 promotes IGF signaling by mediating atypical ubiquitination of IRS-1. J Biol Chem. 2021Jan-Jun; 296: 100739 Epub 2021 May 13. PMID: 33991522; PMCID: PMC8191236
   PubMed Web of Science ®Google Scholar
• Singh R, Karri D, Shen H, et al. TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest. 2018 Jul 2;128(7):3129–3143. Epub 2018 Jun 18. PMID: 29715200; PMCID: PMC6026011.
   PubMed Web of Science ®Google Scholar
• Yao W, Wang X, Cai Q, et al. TRAF4 enhances osteosarcoma cell proliferation and invasion by Akt signaling pathway. Oncol Res. 2014;22(1):21–28. PMID: 25700355; PMCID: PMC7592778.
   PubMed Web of Science ®Google Scholar
• Arora S, Saini S, Fukuhara S, et al. MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases. PloS One. 2013;8:e78023.
   PubMed Web of Science ®Google Scholar